MA55551A - Anticorps anti-hla-c et leurs utilisations - Google Patents

Anticorps anti-hla-c et leurs utilisations

Info

Publication number
MA55551A
MA55551A MA055551A MA55551A MA55551A MA 55551 A MA55551 A MA 55551A MA 055551 A MA055551 A MA 055551A MA 55551 A MA55551 A MA 55551A MA 55551 A MA55551 A MA 55551A
Authority
MA
Morocco
Prior art keywords
hla
antibodies
Prior art date
Application number
MA055551A
Other languages
English (en)
Inventor
Ryan Eberwine
Anne Fourie
Paul H Kim
Carl L Manthey
Hong Zhou
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA55551A publication Critical patent/MA55551A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA055551A 2019-04-04 2020-04-03 Anticorps anti-hla-c et leurs utilisations MA55551A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962829282P 2019-04-04 2019-04-04

Publications (1)

Publication Number Publication Date
MA55551A true MA55551A (fr) 2022-02-09

Family

ID=72662846

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055551A MA55551A (fr) 2019-04-04 2020-04-03 Anticorps anti-hla-c et leurs utilisations

Country Status (6)

Country Link
US (1) US11299545B2 (fr)
EP (1) EP3946452A1 (fr)
JP (1) JP2022527541A (fr)
AU (1) AU2020251028A1 (fr)
MA (1) MA55551A (fr)
WO (1) WO2020202097A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240135852A (ko) * 2022-01-24 2024-09-12 제노백 안티바디 디스커버리 엘엘씨 항-alk1 항체 및 그의 사용 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2347239T3 (es) * 2002-12-02 2010-10-27 Amgen Fremont Inc. Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
ES2430068T3 (es) * 2007-09-26 2013-11-18 U3 Pharma Gmbh Proteínas de unión a antígeno del factor de crecimiento de tipo factor de crecimiento epidérmico de unión a heparina
JP5980202B2 (ja) 2011-05-09 2016-08-31 株式会社ペルセウスプロテオミクス トランスフェリン受容体を特異的に認識できる抗体
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
WO2017058944A1 (fr) * 2015-09-29 2017-04-06 Amgen Inc. Inhibiteurs de l'asgr pour réduire les taux de cholestérol
MA44072A (fr) * 2015-12-17 2018-10-24 Janssen Biotech Inc Anticorps se liant spécifiquement à hla-dr et leurs utilisations

Also Published As

Publication number Publication date
US11299545B2 (en) 2022-04-12
JP2022527541A (ja) 2022-06-02
WO2020202097A1 (fr) 2020-10-08
EP3946452A1 (fr) 2022-02-09
US20200317791A1 (en) 2020-10-08
AU2020251028A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
EP3891183A4 (fr) Anticorps anti-claudine et leurs utilisations
EP3918323A4 (fr) Anticorps anti-gal3 et leurs utilisations
EP3759143A4 (fr) Anticorps anti-tigit et leurs utilisations
MA52773A (fr) Anticorps anti-cd3 et leurs utilisations
EP3958910A4 (fr) Conjugués anticorps anti-cd45-médicaments et leurs utilisations
EP3625263A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
EP3849608A4 (fr) Nouveaux anticorps anti-lilrb4 et leurs utilisations
EP3898691A4 (fr) Anticorps trem2 et leurs utilisations
MA52949A (fr) Anticorps anti-pd-1 et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
MA54955A (fr) Anticorps anti-claudine 6 et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
EP3790586A4 (fr) Anticorps anti-dll3 et leurs utilisations
MA55491A (fr) Anticorps anti-pyroglutamate-amyloïde bêta et leurs utilisations
EP3908603A4 (fr) Anticorps muc1* antivariables et leurs utilisations
EP3962954A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
EP3645563A4 (fr) Anticorps anti-fam19a5 et leurs utilisations
EP3850012A4 (fr) Anticorps anti-tnfrsf9 et leurs utilisations
EP3755714A4 (fr) Anticorps anti-angiopoïétine-2 et leurs utilisations
MA54469A (fr) Anticorps anti-il-27 et leurs utilisations
MA52235A (fr) Anticorps anti-phf-tau et leurs utilisations
EP3672987A4 (fr) Anticorps anti-apéline et leurs utilisations
EP4010368A4 (fr) Anticorps anti-nampt et leurs utilisations
MA55613A (fr) Anticorps anti-intégrine et leurs utilisations
EP3768317A4 (fr) Anticorps anti-il-27 et leurs utilisations